奥浦迈: 奥浦迈：关于延期回复《关于上海奥浦迈生物科技股份有限公司发行股份及支付现金购买资产并募集配套资金的审核问询函》的公告

Group 1 - The company plans to acquire 100% equity of Pengli Biopharmaceutical Technology (Shanghai) Co., Ltd. through a combination of issuing shares and cash payment [1][2] - The company has received an inquiry letter from the Shanghai Stock Exchange regarding the asset acquisition and fundraising, which requires a response within one month [2] - Due to the complexity of the issues raised in the inquiry letter, the company has applied for a one-month extension to submit its response [2][3] Group 2 - The completion of the transaction is subject to multiple conditions, including approval from the Shanghai Stock Exchange and registration consent from the China Securities Regulatory Commission [2] - The company commits to timely information disclosure in accordance with relevant laws and regulations as the transaction progresses [3]